Most antivirals work by stopping the replication of the virus once inside the cell.
Except for Ivermectin that works by restoring the self defence of the cells and their ability to alarm the immune system.
The mechanism of action of this new class of broad-spectrum antivirals is entry inhibition. It is designed to latch on to entry proteins like the spike proteins, thereby neutralizing the virus's ability to enter the cell.
Similar to the monoclonal antibodies. Antibodies have to be very specific to a small part of the virus and this new stuff can be a little more unspecific, that's why it's called a broad-spectrum antiviral. But it still needs to get tailored to the targeted virus.
> Most antivirals work by stopping the replication of the virus once inside the cell.
Except for Ivermectin that works by restoring the self defence of the cells and their ability to alarm the immune system.
> The mechanism of action of this new class of broad-spectrum antivirals is entry inhibition.
> It is designed to latch on to entry proteins like the spike proteins, thereby neutralizing the virus's ability to enter the cell.
Similar to the monoclonal antibodies. Antibodies have to be very specific to a small part of the virus and this new stuff can be a little more unspecific, that's why it's called a broad-spectrum antiviral. But it still needs to get tailored to the targeted virus.
You aren't wrong.
You aren't wrong.
(post is archived)